02137

0.9952.58%
AL

Ankang Li

COO, Joint Secretary & Executive Director

Dr. Ankang Li, C.F.A., J.D. & Ph.D., serves as Executive Director of Brii Biosciences Limited from September 30, 2022 and has been its Joint Company Secretary since April 8, 2021 and also serves as Chief Executive Officer of TSB Therapeutics since September 2022 and its COO since November 18, 2025. He served as the Operating Advisor at One Six 8 Ventures. He was the chief financial officer and the chief strategy officer of the Company from September 1, 2020 to November 18, 2025 and from March 22, 2022 to November 18, 2025, respectively. Dr. Li is accountable for Brii’s corporate finance & accounting, reporting & control, legal, Investor Relations, corporate communications, operation excellence and strategy development. Before joining Brii Bio, he was the CFO of Terns Biopharmaceuticals to develop and deploy financial and corporate strategies and budget. Prior to Terns, Dr. Li was the Executive Director of Healthcare Investment Banking at Goldman Sachs responsible for Asia ex-Japan investment banking and led many high-profile IPOs for biotechnology and other healthcare clients. Dr. Li also worked in Merck Asia Pacific Innovation Hub, overseeing business development and licensing transactions in the region. Before that Dr. Li worked at both Davis Polk and Ropes & Gray, advising clients on capital markets and M&A transactions. His working career started in the Salk Institute as a biomedical researcher. Dr. Li received a Juris Doctor degree from the University of Chicago Law School, a Ph.D. degree in Biomedical Sciences from Baylor College of Medicine, a Master of Science degree in Biological Sciences from the National University of Singapore and a Bachelor of Science degree in Biochemistry from Fudan University. He is also a chartered Financial Analyst (CFA).

Positions